- AMRX Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing
Amneal Pharmaceuticals (AMRX) 8-KEntry into a Material Definitive Agreement
Filed: 7 May 18, 7:44am
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Impax Laboratories, Inc.:
We consent to the use of our report dated March 1, 2018, with respect to the consolidated balance sheets of Impax Laboratories, Inc. and its subsidiaries as of December 31, 2017 and 2016, and the related consolidated statements of operations, comprehensive (loss) income, changes in stockholders’ equity and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes and financial statement schedule (collectively, the “consolidated financial statements”), incorporated herein by reference.
/s/ KPMG LLP
Philadelphia, Pennsylvania
May 7, 2018
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.